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 Natural Killer (NK) cells are the only innate lymphoid cells with cytotoxic 
capacity. They play a critical role in tumor surveillance and viral immunity through direct 
target cell lysis. As their target cells are host tissue, cytotoxic capacity must be tightly 
regulated. NK cells undergo a terminal maturation program that coincides with the 
acquisition of properly-regulated cytotoxic function. Three stages of the program have 
been defined by the sequential expression of two proteins on the cell surface: CD27 and 
CD11b.  Immature NK cells are CD27+CD11b-, then CD27+CD11b+, and finally CD27-
CD11b+. Although these stages have been defined for some time, the molecular 
underpinnings that govern each step remain elusive. 
 Members of the intramembrane aspartyl protease family play important roles in 
innate and adaptive immunity. Signal peptide peptidase-like 3 (SPPL3) has recently been 
identified in cell lines as a positive regulator of calcium flux in the T cell receptor 
pathway, as well as a bona fide protease regulating glycosyl transferase expression. 
However, there are no known roles for SPPL3 in vivo. 
To study the effects of tissue-specific deletion in mice, a floxed allele of SPPL3 
was generated and crossed to several drivers of Cre-recombinase. Using CRISPR/Cas9 
gene editing, a non-conditional protease-dead SPPL3 allele was generated. Immune 
system function was probed using standard flow cytometry, cell culture, and molecular 
biology techniques. 
Deletion of SPPL3 within the immune system resulted in a loss of mature, 
CD11b+ NK cells. This phenotype was cell autonomous and required SPPL3 protease 
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activity. SPPL3 did not appear to act through any of the known pathways regulating NK 
cell maturation.  
This study establishes SPPL3 as an important checkpoint in NK cell maturation. 
SPPL3 protease activity is required in a cell-autonomous manner for NK cells robust 
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Natural Killer Cells 
 
 Natural killer cells are a small population of innate lymphoid cells that play an 
important role in tumor surveillance and viral clearance through direct target cell lysis 
(1). Target cell killing must be tightly regulated in order to protect the host from abberant 
tissue damage.  
Cytotoxic activity is regulated by the balance of signals from activating and 
inhibtory receptors (2, 3). One of the major inhibitory ligands for NK cells is MHC class 
I molecules (4). Tumors and virally infected cells often escape cytotoxic T cell responses 
by preventing MHC class I molecules from expressing on the cell surface. Target cell 
lysis is achieved by one of several mechanisms that induce target cell apoptosis: 
cytotoxic molecule release (perforin and granzymes) into the target cell, Fas ligand 
activation of Fas on the target cells, or tumor necrosis-factor related apoptosis-inducing 
ligand (TRAIL) activation of TRAIL receptor on the target cells (5). 
In mice, NK cells mostly arise from precursors in the bone marrow before 
migrating to populate peripheral organs (6). Small populations exist that appear to have 
developed in peripheral organs, though the significance of these subsets has not been 
established (7).  
Natural killer cells undergo a highly-ordered maturation program and are not 
considered mature until they express a diverse repertoire of activating and inhibitory 
receptors to regulate cytotoxic activity (8, 9). Early differentiation events occur in the 
bone marrow, followed by a terminal maturation program that coincides with egress from 
the bone marrow and colonization in the periphery (10). There are three stages during the 
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terminal maturation phase: first CD27+CD11b-, then CD27+CD11b+, and finally CD27-
CD11b+. Previous reports independently suggest that CD11b- NK cells have lower 
cytotoxiciy than CD11b+ NK cells, and that CD27-CD11b+ NK cells have lower 
cytotoxicity than CD27+CD11b+ NK cells (10, 11).  
 Although these stages have been accepted for several years, surprisingly little is 
understood about the molecular mechanisms that regulate the functional transitions.  
Most of the mechanistic understanding lies at the final stage of development, in the 
progression from the CD27+CD11b+ stage to the CD27-CD11b+ stage.  
The most well-studied pathway regulating NK cell maturation is the transcription 
factor, Tbet (encoded by the Tbx21 gene). Tbet deficiency results in a block at the 
CD27+CD11b+ stage (12). Tbet is required to turn on Zeb2, which is required for 
progression through this stage (13). Tbet is also required for the expression of the 
sphingosine 1-phosphate receptor (S1P5), which is required for mature NK cells to egress 
from the bone marrow (14). A negative regulator of the pathway was recently indentified: 
Foxo1 binds the Tbx21 promoter in NK cells to inhibit NK cell maturation (15). 
There are several less-well understood contributions to NK cell maturation in the 
final stage as well. Aiolos deficiency prevents cells from downregulating CD27, leading 
to an apparent block at the CD27+CD11b+ maturation stage, but with unusually high 
CD27+KLRG1+ cell numbers (16). Other genes whose deletion results in a block at the 
CD27+CD11b+ stage are: Dok1 and Dok2, Cardif (MAVS), MYSM1, and microRNA-
15/16 (17–20).  
In addition to these cell-instrinsic requirements, there are two cell-extrinsic 
mechanisms regulating the CD27+CD11b+-to-CD27-CD11b+ transition. Mice depleted 
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of either neutrophils or monocytes showed a block in the CD27+CD11b+ maturation 
stage (21, 22), though the pathways required for this are not understood. 
There is far less known about the transition from CD27+CD11b- to 
CD27+CD11b+. Deletion of the transcription factor eomesodermin (eomes) prevents 
maturation past this stage (12). Eomes is thought to regulate the expression of several 
homing receptors and Ly49 receptors, and somehow regulates steady-state proliferation. 
IL-15 signaling through mTOR is reported to regulate the proliferation of immature, 
CD27+CD11b- NK cells in the bone marrow (23) which leads to a loss of both CD11b-




Proteases are enzymes that cleave proteins through hydrolysis. Paradoxically, a 
group of proteases exist that cleave target proteins within the hydrophobic core of the 
lipid bilayer. These are the intramembrane proteases. Similar to their cytoplasmic 
counterparts, intramembrane proteases are grouped into families based on their catalytic 
mechanism: serine/threonine, aspartyl, and metalloproteases (24).  There are no reported 
intramembrane cysteine proteases (25). 
The first discovered intramembrane protease was the Golgi-resident Site-2 
protease (S2P), a metalloprotease that is involved in sterol sensing and fatty acid 
synthesis (26). S2P cleavage is regulated by at least two factors. First, the target, sterol 
regulatory element-binding protein (SREBP), is sequestered in the endoplasmic reticulum 
(ER) under normal circumstances. When cholesterol is low, SREBP is transported to the 
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Golgi (27), where it must first be clipped by the Site-1 protease before becoming a 
suitable substrate for S2P (28). 
The intramembrane serine protease family is characterized by the rhomboids. The 
rhomboid superfamily is involved in regulating epidermal growth factor receptor (EGFR) 
signaling through the processing of precursor transmembrane ligands to a soluble, 
secreted product. In Drosophila, the ligand Spitz is retained in the ER, whereas 
Rhomboid-1 resides in the Golgi (29). The Star protein is required to shuttle Spitz to the 
Golgi for cleavage by Rhomboid-1 (30). In contrast to S2P cleavage, Rhomboid-1 does 
not appear to require a sheddase to prepare the substrate.  
The intramembrane aspartyl protease family is subdivided into two subfamilies: 
the presenillins and the signal peptide peptidases (SPP). This family is unified by the YD 
and GxGD catalytic motif (31). The presenillins are the catalytic component of the γ-
secretase complex, which processes the amyloid precursor protein (APP) C-terminal 
fragment after its initial cleavage. Plaques formed by accumulation of the amyloid-β 
peptide created by presenillin are thought to drive familial Alzheimer’s disease (32–34).  
The γ-secretase complex also plays a role in Notch signaling. The Notch receptor 
on the cell surface is a dimer containing one transmembrane peptide (35). When ligand 
from a neighboring cell binds the receptor, cleavage occurs in the transmembrane 
segment to release the Notch intracellular domain (NICD), which translocates to the 
nucleus and plays a role in transcription of target genes (36). In addition to proteolytic 
function, presenilins are thought to form ER calcium leak channels (37).  
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Signal Peptide Peptidases In The Immune System 
 
There are five signal peptide peptidase (SPP) and SPP-like (SPPL) genes: SPP, 
SPPL2a, SPPL2b, SPPL2c, and SPPL3. SPPL2c is thought to be a pseudogene as it lacks 
introns, is highly polymorphic, and has not been detected at the protein level (38). The 
topology of the catalytic aspartic acid residues within the membrane is reversed between 
presenillins and SPPs (39). This suggests that while presenillins will cleave type I 
transmembrane targets, the SPP family members will cleave type II oriented 
transmembrane substrates.  
SPP resides in the ER and cleaves the remaining signal peptide from classical 
MHC class I molecules (40). These cleaved peptides are then loaded into nonclassical 
MHC molecules, HLA-E in humans or Qa-1 in mice, which serve as negative regulators 
of cytotoxic natural killer (NK) cell responses against host cells (41–43). The signal 
peptide from preprocalcitonin, overexpressed in several cancers, is also cleaved by SPP 
and can be presented by MHC class I molecules to induce cytotoxic T lymphocyte 
responses (44).  
SPPL2a is a Golgi-resident protease. One well-characterized substrate of SPPL2a 
is the invariant chain, CD74 (45–47). The invariant chain is a transmembrane protein that 
temporarily loads into the peptide groove of MHC class II proteins during their transport 
from the ER to endosomes (48). Upon entry into the endosomes, CD74 is clipped into a 
peptide which remains in the MHC class II groove, and N-terminal transmembrane 
fragment (NTF). This NTF is processed for recycling by SPPL2a. SPPL2a deficiency 
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leads to a loss of mature B cells and dendritic cells (DCs) due to build up of the 
uncleaved NTF, which leads to cell death.  
SPPL2a and SPPL2b contribute to the cleavage of another interesting substrate: 
the cytokine tumor necrosis factor (TNF)-α (49). In this model, TNF- α is synthesized as 
a transmembrane precursor, then the secreted cytokine is clipped from the membrane, 
leaving behind a short NTF. The NTF is then processed, at least in vitro, by SPPL2a and 
SPPL2b. Although TNF- α itself is unaffected, DCs treated with pan-SPP inhibitors are 
unable to produce IL-12. The NTF cleaved by SPPL2a/b is thought to translocate to the 
nucleus to regulate IL-12 transcription by an unknown mechanism.  
 
Signal Peptide Peptidase-3 (SPPL3) 
 
SPPL3 is a poorly-understood member of this family. By sequence homology, 
SPPL3 is closer to SPP than to SPPL2a/b/c (39). The sequence of SPPL3 is highly 
conserved within the animal kingdom (31), suggesting an important, though elusive, 
evolutionary role for the protease. Microarray analysis shows nonspecific expression 
throughout the body. It is not thought to be glycosylated. Loss of SPPL3 or expression of 
a protease-dead mutant in zebrafish led to a cell death phenotype in the central nervous 
system (50). SPPL3 is localized primarily to the ER, though there may be some 
expression later in the secretory pathway (50, 51).  
There are no confirmed roles for SPPL3 in human disease. However, SPPL3 was 
identified in a genome-wide association study of inflammatory disease in Sardinians (52), 
but the single nucleotide polymorphism was near another gene and in low frequency.  
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SPPL3 was also identified in exome sequencing from one family with non-BRCA-
associated breast cancer (8).  
It was shown that SPPL3 is competent to cleave artificial substrates when 
transfected (53, 54), but it was only two years ago that an endogenous substrate was 
identified (55, 56). In these papers, SPPL3 acts as a sheddase to liberate glycosyl 
transferases from the ER, with effects on global glycosylation levels. Loss of SPPL3 
results in the retention of the glycosyl transferases and hyperglycosylation of target 
proteins. This is in contrast to other intramembrane aspartyl proteases, which require 
prior sheddase activity (54, 55). Additional work on the secreted, glycosylated proteins 
yielded many additional candidate substrates (56), though these all need further 
confirmation.  All protease substrates will need to be confirmed in vivo to determine their 
relevance. 
In addition to protease-dependent functions, SPPL3 was recently identified as a 
regulator of NFAT signaling through a protease-independent manner (51). Here, SPPL3 
regulates the interaction between Stim1 and Orai1 molecules to enhance calcium flux 
downstream of T cell receptor (TCR) signaling. This function has not yet been 
demonstrated in vivo.  
To date, there are no reported functions of SPPL3 in vivo. In chapter II we took an 
unbiased approach to ask what the in vivo role of SPPL3 might be and identified SPPL3 
as a key survival molecule in mature NK cells. This study presents the first line of 
evidence that SPPL3 is a key checkpoint in NK cell maturation and continues to expand 
the role for intramembrane proteases in innate and adaptive immunity. In addition, this 
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work establishes several in vivo models for studying SPPL3 that will be widely 
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Abstract 
NK cell maturation is critical for normal effector function and the innate immune 
response to tumors and pathogens. However, the molecular pathways that control NK cell 
maturation remain largely undefined. Here, we investigate the role of SPPL3, an 
intramembrane aspartyl protease, in murine NK cell biology. We find that deletion of 
SPPL3 in the hematopoietic system reduces numbers of peripheral NK cells, clearance of 
MHC Class I-deficient tumors in vivo, and cytotoxicity against tumor cells in vitro. This 
phenotype is concomitant with reduced numbers of CD27+CD11b+ and CD27-CD11b+ 
NK cells, indicating a requirement for SPPL3 in efficient NK cell maturation. NK cell-
specific deletion of SPPL3 results in the same deficiencies, revealing a cell-autonomous 
role for SPPL3 in these processes. CRISPR/Cas9 genomic editing in murine zygotes was 
used to generate knock-in mice with a catalytically compromised SPPL3 D271A allele. 
Mice engineered to express only SPPL3 D271A in NK cells phenocopy mice deleted for 
SPPL3, indicating a requirement for SPPL3 protease activity in NK cell biology. Our 
results identify SPPL3 as a cell-autonomous molecular determinant of NK cell 





As founding members of the innate lymphoid cell family, natural killer (NK) cells 
are critically important for tumor surveillance and clearance of virally-infected cells by 
the innate immune system (1). Robust NK cell effector function depends upon normal 
NK cell development and maturation, which are governed by cell-intrinsic transcription 
factors as well as cytokines, including IL-15 (12, 57, 58). The major source of NK cell 
precursors and the site of their development in mice is the bone marrow (6). After 
development, NK cells migrate into the periphery and populate all the organs of the body. 
During the final stages of development, NK cells undergo an ordered maturation program 
defined by the expression of the tumor necrosis factor (TNF) family member CD27 and 
the integrin CD11b. NK cells progress from an immature CD27+CD11b- stage to an 
intermediate CD27+CD11b+ stage, and finally to a CD27-CD11b+ stage (9–11, 59). 
Progression through these stages is required for optimal NK cell activity, and it occurs at 
the same time NK cells acquire the full complement of activating and inhibitory receptors 
that control their response to targets. Although the maturation steps have been defined by 
expression of these markers, the molecular details that govern these transitions are poorly 
understood.  
The intramembrane aspartyl protease family is a class of multi-pass 
transmembrane proteins with diverse proteolytic roles in biology (31, 39). The family 
includes presenilin-1 and -2, and the signal peptide peptidase (SPP)-like subfamily 
members SPP, SPPL2a, SPPL2b, SPPL2c, and SPPL3. All intramembrane aspartyl 
proteases share YD and GXGD motifs that function in catalysis. Presenilins cleave Type 
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I transmembrane proteins and function as the catalytic subunits of the γ-secretase 
complex. The SPP-like subfamily members cleave Type II transmembrane proteins due 
to their opposite orientation in the lipid bilayer, and function autonomously. 
Recent studies have highlighted emerging roles in innate and adaptive immunity 
for SPP-like subfamily members. SPP cleaves the signal peptide from MHC class I 
proteins for presentation on HLA-E, which regulates NK cell function (40, 60), and also 
generates peptides for presentation by MHC class I, which impacts T cell activity (44). 
SPPL2a controls B cell and dendritic cell (DC) survival through cleavage of the N-
terminal fragment of invariant chain, CD74, the build-up of which is toxic to these cells 
(45–47). SPPL2a can also cleave Fas ligand to generate an intracellular domain that 
inhibits B and T cell activation downstream of antigen receptor engagement (61). 
SPPL2a and SPPL2b are also reported to cleave TNF-α, releasing an intracellular domain 
that elicits IL-12 production in DCs (49). 
SPPL3 is perhaps the least understood member of this family. Both protease-
dependent and protease-independent functions have very recently been described for 
SPPL3. In a protease-independent manner, SPPL3 functions in the endoplasmic reticulum 
(ER) in T cells to promote store-operated calcium entry in response to T cell receptor 
engagement by enhancing the interaction between STIM1 and Orai1 (51). SPPL3 has 
also been shown to function as a protease in cell lines and murine embryonic fibroblasts 
(MEFs) to regulate the extent of constitutive complex glycosylation by targeting several 
glycosylation enzymes for cleavage and shedding from the ER or Golgi (55, 56). 
 In order to study SPPL3 function in the immune system, we generated and 
evaluated mice with a conditional SPPL3 allele that allowed targeted, tissue-specific 
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SPPL3 deletion. Here we report an obligate, cell-autonomous, protease-dependent role 
for SPPL3 in NK cell maturation and cytotoxicity.  
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Materials And Methods 
 
Mice 
Mice containing two loxP sites flanking the third exon of SPPL3 on chromosome five 
were generated by conventional embryonic stem (ES) cell homologous recombination by 
Ingenious Targeting Limited in the C57Bl/6N x 129/SvEv strain background. These mice 
were back-crossed to C57Bl/6J (The Jackson Laboratory) mice for at least eight 
generations before crossing to Cre-containing strains. Sox2-Cre- (62) and Vav1-iCre-
expressing mice (63) were purchased from The Jackson Laboratory. NKp46-iCre mice 
(9) were a gift from G. Trinchieri (NCI, Bethesda), with permission from E. Vivier 
(INSERM, France). 
PCR was used to confirm the genotypes of all mice. Males and females at least 7 weeks 
old were used with age- and sex-matched littermate controls. All mice were maintained in 
accordance with the Johns Hopkins University Institutional Animal Care and Use 
Committee. The SPPL3 D271A allele was generated by CRISPR/Cas9 genome 
engineering (64). An SPPL3-specific, sgRNA-encoding sequence, 5’-
atcggggacattgtgatgcc-3’, was cloned into the BbsI site of pX330 (Addgene), amplified 
from pX330 with a leading T7 promoter by PCR, in vitro transcribed using the HiScribe 
T7 in vitro transcription kit (New England Biolabs), purified using the MEGAclear Kit 
(Ambion) and resuspended in water. A T7 promoter was cloned into pX330 directly 
upstream of Cas9 at the AgeI site, to create pX330+T7. Cas9 mRNA was in vitro 
transcribed using NotI-linearized pX330+T7 and the mMESSAGE mMACHINE T7 
Ultra kit (Ambion), purified by LiCl precipitation, and resuspended in water. The 
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case letters indicate mutations). An endogenous MslI restriction site was destroyed by the 
mutation, and a novel PvuI site was engineered to aid genotyping. The HDR oligo was 
purchased from IDT (4nM Ultramer) and resuspended in water. 25 ng/ml Cas9 mRNA, 
12.5 ng/ml sgRNA and 25ng/ml HDR DNA oligo were injected into C57Bl/6J embryos 
generated by The Transgenic Core Laboratory at the Johns Hopkins University School of 
Medicine. Three founders were obtained from a cohort of 23 live pups and crossed to 
C57Bl/6J mice to demonstrate germline transmission. PCR followed by overnight PvuI 
digestion was used to confirm the presence of the mutant allele at each generation. 
Heterozygous pups from the N1 generation were used for survival curves and further 
breeding. Survival curves were completed with at least 100 pups from each founder. The 
relevant SPPL3 locus from one founder line was sequenced and this line was used in all 
other experiments. The top two off-target sites predicted by the server at CRISPR.mit.edu 
were sequenced and showed no evidence of Cas9 activity.  
 
Reagents 
Antibodies were purchased recognizing mouse CD3 (145-2C11, BD), CD19 (1D3, BD), 
Ter119 (TER119, BD), Gr-1 (RB6-8C5, BD), CD122 (TM-β1, Biolegend), CD49b 
(DX5, BD and Biolegend), CD11b (Mac-1, BD), Ki67 (16A8, Biolegend), B220 (RA3-
6B2, BD), CD8-α (53-6.7, BD), NK1.1 (PK136), NKG2D (CX5), NKp46 (29A1.4, 
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Biolegend), CD27 (LG.7F9, eBioscience), phospho-S6 (235/6) (D57.2.2E, Cell 
Signaling), CXCR4 (2B11, eBioscience), Eomesodermin (Dan11Mag, eBioscience), 
KLRG1 (2F1/klrg1, Biolegend), CD51 (RMV-7, eBioscience), Ly49H (3D10, 
eBioscience), CD69 (H1.2F3, BD), NKG2A/C/E (20D5, BD), Ly49G2 (eBio4D11, 
eBioscience), CD127 (A7R34, Biolegend), CXCR3 (CXCR3-173, BD), CD98 (RL388, 
Biolegend), Ly49D (4E5, Biolegend), phospho-STAT5 (47/Stat5(pY694), BD), GAPDH 
(D16H11, Cell Signaling), Tubulin (AA12.1, Developmental Studies Hybridoma Bank), 
and MGAT5 (clone 706824, R&D Systems). The SPPL3 antibody was previously 
described (51).  
Concanavalin A, CellTrace CFSE, and CellTrace Violet (CTV) proliferation kits were 
purchased from Molecular Probes. Annexin V was purchased from Biolegend. Murine 
recombinant IL-15 was purchased from Peprotech. PHA-L was purchased from Life 
Technologies. IC fixation buffer, and FoxP3 fixation and permeabilization buffer and 
concentrate, and 10x permeabilization buffer were all purchased from eBioscience. 
Cytofix and Permeabilization buffer IV were purchased from BD Bioscience. 
 
Flow cytometry 
Organs were harvested into media (RPMI 1640, 5% FBS, 1% penicillin/streptomycin, 1% 
L-glutamine) and dissociated using frosted glass slides. Single cell suspensions were 
obtained by passing the cells over a 70 µm filter. Liver cells were spun over a 35% 
Percoll (Sigma) solution to separate lymphocytes (pelleted) from hepatocytes (top layer). 
Red blood cells (RBCs) were lysed using Ack lysing buffer (Quality Biologics). The final 
cell pellets were resuspended in PBS and counted using trypan blue exclusion. Negative 
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isolation was performed according to manufacturer’s directions (Miltenyi) and enriched 
over LS columns.  
Surface staining was carried out in FACS buffer (PBS, pH 7.4, 0.5% BSA, 2mM EDTA, 
0.02% sodium azide) on ice for 30-60 minutes.  
For intracellular staining of eomesodermin, the eBioscience Foxp3 fixation/ 
permeabilization kit was used.  
Annexin V staining was performed in 1x Annexin V binding buffer (10mM HEPES, pH 
7.4, 140mM NaCl, 2.5mM CaCl2) for 15 minutes after surface staining. Additional 
Annexin V binding buffer was added and samples were run immediately. 
Lineage markers used in all figures are CD3, CD19, Ter119, and Gr-1. 
Data was collected on an LSR II flow cytometer (BD) and analyzed using FlowJo 
software (TreeStar). 
For sorted cells, after the final wash, cells were passed through a 35 µm filter and sorted 
on a FACS Aria (BD) at the Johns Hopkins Ross Flow Cytometry Core.  
 
RMA/s killing assay 
RMA and RMA/s cells were a gift from J. Sun (MSKCC, New York). RMA/s cells were 
loaded with 2.5µM CFSE and RMA cells with 5µM CTV according to manufacturer’s 
directions. Cells were mixed in even ratios and injected (5x105 cells each) 
intraperitoneally into mice. 48 hours later, peritoneal lavage was performed by injecting 
4ml PBS using a 27G needle into the cavity and massaging. The fluid was collected with 
a 22G needle. The ratio of RMA/s cells recovered is reported as a fraction of the total 
CFSE+ and CTV+ cells collected. 
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YAC-1 lysis assay 
Splenic NK cells were isolated using the NK Negative Isolation II Kit (Miltenyi), then 
stained for CD49b (DX5) expression. YAC-1 cells were loaded with 500nM CFSE 
according to manufacturer’s directions. Equivalent numbers of CD49b+ cells were mixed 
in 96-well plates with YAC-1 cells in the indicated effector: target ratios. After 4-5 hour 
culture, cells were stained with Annexin V. YAC-1 lysis was calculated as the fraction of 
Annexin V+ cells as a percentage of CFSE+ cells, and is reported as the percent specific 
lysis in each experiment. 
For Figure 2.7, spleens from three C57Bl/6J mice were pooled. After isolation, cells were 
stained and sorted for Gr-1-DX5+ cells and CD27 and CD11b expression. Cells were 
counted and co-cultured with CFSE-loaded YAC-1 cells for 3.5 hours at a 2:1 E:T ratio 
before Annexin V staining. 
 
Western Blots 
For Figure 2.1a, C57Bl/6J spleens were harvested and sorted on the indicated markers. 
Splenocytes were isolated using the CD4+ T cell isolation kit, CD8a+ T cell isolation kit, 
Pan-B cell isolation kit II, or NK isolation kit II (Miltenyi). For NKp46-iCre strains, cells 
were further sorted for Gr-1-DX5+ cells. Isolated cells were lysed in equal volumes IP 
lysis buffer (150mM NaCl, 50mM HEPES pH 7.9, 1mM EDTA, 10% glycerol, 1% 
igepal) for 1 hour at room temperature. Sorted cells were lysed in equivalent IP lysis 
buffer volume per cell. After clearing cell debris, total protein of isolated cells was 
analyzed by Bradford assay (Bio-Rad). Buffer D (150 mM Tris-HCl at pH 6.8, 15% SDS, 
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12.5% (v/v) 2-mercaptoethanol, 25% (v/v) glycerol, and 0.02% (w/v) bromphenol blue) 
was added and lysates were separated on a 12% SDS-PAGE gel then transferred to PVDF 
membranes. Membranes were stained with Ponceau S (0.1% Ponceau S w/v, 5% acetic 
acid v/v) to confirm equivalent loading, then blocked in 5% milk in TBST 1 hour to 
overnight. Anti-SPPL3 (1:20,000 dilution) and anti-MGAT5 (1:250 dilution) antibodies 
were incubated overnight. Anti-GAPDH (1:2000-5000 dilution) and anti-Tubulin 
(1:20,000 dilution) antibodies were incubated 1 hour to overnight. HRP-conjugated 
secondary antibodies (Santa Cruz) were incubated at 1:2000 dilution for 1 hour and HRP 
was detected by Clarity ECL Western substrate (SPPL3 and MGAT5, Bio-Rad) or ECL 




Splenic or bone marrow lymphocytes were harvested, RBCs were lysed, and cells were 
aliquotted into 96-well U-bottom plates. 2x IL-15 or media alone was added to the 
cultures and incubated at 37ºC for 40 minutes. Cells were washed once with PBS and 
stained for surface proteins. After another PBS wash, cells were fixed in pre-warmed BD 
Cytofix for 10 minutes at 37ºC. Cells were washed with PBS, then resuspended in 1x 
permeabilization buffer IV (BD) for 15 minutes. After a spin, cells were resuspended in 
FACS buffer with the phospho-S6 and phospho-STAT5 antibodies for 45 minutes at 4ºC. 
 
NK cell proliferation 
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Splenic NK cells were isolated and loaded with 10µM CFSE for 15 minutes according to 
manufacturer’s instructions. 2.5x104 cells were plated in 96-well U-bottom plates and 2x 
IL-15 or media alone was added. Cells were cultured for 3 days. After a wash, cells were 
stained for DX5 followed by AnnexinV staining for proliferation analysis. 
 
PCR 
For tail cells, tissue was digested in proteinase K (25U/ml) 2 hours to overnight in Laird’s 
buffer (100mM Tris pH 8.5, 5mM EDTA, 0.2% SDS 400mM NaCl). DNA was extracted 
by ethanol precipitation and the pellet was resuspended in 0.1X TE.  





SPPL3 is necessary for normal numbers of peripheral NK cells 
 To explore a role for SPPL3 in the immune system, we assayed its expression in 
B cells, T cells, and NK cells sorted from murine splenocytes (Fig. 2.1A). All cells 
assayed expressed SPPL3, but NK cells exhibited the highest levels, suggesting a 
potential role for SPPL3 in NK cell biology.  
 To determine an in vivo role for SPPL3, we generated mice with an allele of 
SPPL3 in which the third exon is flanked by loxP sites, SPPL3fl/+. We bred SPPL3fl/+ 
mice to Sox2-Cre mice to generate a constitutive null allele, SPPL3-/+, then bred these 
mice to homozygosity to evaluate the effects of global SPPL3 deletion. All genotypes 
were born in Mendelian ratios, but SPPL3-/- mice were smaller than their littermates and 
died of undetermined cause shortly after birth (Fig. 2.1B, and data not shown).  
 We next bred SPPL3fl/fl mice to Vav1-iCre mice to investigate hematopoietic cell-
specific effects of SPPL3 deletion. SPPL3fl/fl /Vav1-iCre (Vav1-SPPL3 KO) mice were 
born at Mendelian ratios and were overtly healthy. SPPL3fl/+/Vav1-iCre, and SPPL3fl/fl 
mice were used as controls (Vav1-SPPL3 WT). Vav1-SPPL3 KO mice displayed normal 
numbers of T (CD3+CD4+, CD3+CD8+) and B cells (CD19+B220+) in the spleen (Fig. 
2.1C). Western blot analysis confirmed that SPPL3 was completely excised in each cell 
type, excluding the possibility that Vav1-iCre is ineffective in these cell types (Fig. 
2.1D). Thus, SPPL3 is dispensable for normal T and B cell numbers. In contrast, the 
number of NK cells (Lin-CD122+DX5+) in Vav1-SPPL3 KO mice was reduced about 
twofold in the spleen, and threefold in the liver, but was normal in the bone marrow (Fig. 
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2.1E, Fig. 2.2). The remaining NK cells in the spleen showed complete excision of 
SPPL3, indicating there was no selection for non-recombined cells (Fig. 2.1F). The data 
indicate that SPPL3 is selectively required for normal numbers of peripheral NK cell 
populations. 
 To test whether the reduction in NK cell numbers in Vav1-SPPL3 KO mice 
resulted in a functional defect, we injected mice with equal numbers of the MHC class I-
deficient tumor cell line, RMA/s, and the MHC class I-sufficient parental line, RMA, and 
compared relative cell recovery after 48 hours. NK cell killing in control mice resulted in 
1.5% recovery of RMA/s cells, while the recovery in Vav1-SPPL3 KO mice was 7%, 
indicating reduced NK cell function (Fig. 2.1G). To exclude total NK cell number and 
migration in vivo as factors contributing to the cytotoxic defect, we tested equal numbers 
of splenic NK cells (DX5+) from Vav1-SPPL3 KO and control mice in a YAC-1 target 
lysis assay in vitro. NK cells from Vav1-SPPL3 KO mice had approximately 60% of the 
cytotoxic activity seen in control mice across a range of effector to target ratios (Fig. 2.1 
H), indicating an important role for SPPL3 in NK cell cytolytic function. 
 
SPPL3 regulates NK cell maturation 
We next addressed whether the reduced NK cell frequency and activity in Vav1-
SPPL3 KO mice was associated with altered receptor expression. NK cells showed 
changes in all of the receptors tested (Fig. 2.3 A). At the population level, the percent of 
NK cells that were NKG2D+ in the spleen was moderately reduced from 97% to 88%. 
NK1.1+ NK cells were also moderately reduced from 99% to 89%. The loss of NKp46+ 
NK cells was somewhat larger, from 97% to 72%. The most significant change was in 
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CD11b+ NK cells, from 81% to 38%, a twofold loss. The same fold changes in these 
populations were seen in the bone marrow (Fig. 2.3 B).  
On a per cell basis, NK1.1 expression on splenic NK cells in Vav1-SPPL3 KO 
mice was reduced from 82% of the maximum fluorescence intensity to only 42% on 
positively staining cells. NKp46 was moderately reduced, from 82% to 63% of the 
maximum, and CD122 expression was reduced from 89% to 72%. No significant change 
in NKG2D levels was observed. DX5 expression on Vav1-SPPL3 KO cells was reduced 
to 76% of control mice (Fig. 2.3 C). Interestingly, similar fold reductions in these 
receptors were observed in the bone marrow of Vav1-SPPL3 KO mice, where NK cell 
numbers were normal. The most dramatic difference in expression levels between Vav1-
SPPL3 KO and control mice was CD11b, an integrin that marks terminal maturation in 
NK cells (59), which was reduced 2.7-fold, from 72% to 27%, on splenic NK cells and 
88% to 50% on bone marrow NK cells in Vav1-SPPL3 KO mice. This prompted us to 
evaluate NK cell maturation in Vav1-SPPL3 KO and control mice.  
NK cells mature sequentially from CD27+CD11b- to CD27+CD11b+ to CD27-
CD11b+ cells. NK cells in Vav1-SPPL3 KO mice displayed a twofold increase in the total 
number of immature, CD27+CD11b- cells in the spleen and bone marrow. Vav1-SPPL3 
KO mice showed a threefold loss of CD27+CD11b+ in the spleen and a twofold loss in the 
bone marrow (Fig. 2.3 D and E), consistent with a partial block in maturation at the 
CD27+CD11b- stage. Vav1-SPPL3 KO mice exhibited a 2.6-fold reduction in the most 
mature CD27-CD11b+ NK cells in the bone marrow, and a 4.9-fold reduction of CD27-
CD11b+ cells in the spleen. Thus, the absence of SPPL3 in the hematopoietic system 
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resulted in the reduced expression of several NK cell surface receptors and a dramatic 
defect in NK cell maturation.  
 
SPPL3 is required in a cell autonomous manner for NK cell development and function 
 Previous studies have determined that other cells in the hematopoietic 
compartment can influence NK cell maturation and function (21, 22), leaving open the 
possibility that the effects on NK cells observed in Vav1-SPPL3 KO mice might be cell-
nonautonomous. To test whether the requirement for SPPL3 in NK cell maturation and 
function was cell-autonomous, we bred the NK cell-specific NKp46-iCre (9) onto the 
SPPL3fl/fl background. SPPL3fl/fl, SPPL3fl/+, SPPL3 fl/+/NKp46-iCre mice were all used as 
controls (NKp46-SPPL3 wt). SPPL3fl/fl/NKp46-iCre mice (NKp46-SPPL3 KO) had a 
fourfold reduction in NK cell number in the spleen compared to control mice. In the bone 
marrow there was a 1.5-fold reduction in NKp46-SPPL3 KO mice (Fig. 2.4 A). Western 
blot analysis of NK cells sorted from the spleen confirmed efficient SPPL3 deletion in 
these cells, again ruling out selection for non-recombined cells (Fig. 2.4 B). RMA/s cells 
were not killed as efficiently in NKp46-SPPL3 KO mice, which had 6.5% recovery of the 
tumor cells, compared to control mice, which had 1.8% recovery (Fig. 2.4 C). Splenic 
NK cells isolated from NKp46-SPPL3 KO mice displayed 53% of control levels of YAC-
1 killing in vitro (Fig. 2.4 D), indicating a cell-autonomous role for SPPL3 in NK cell 
frequency and cytolytic function.  
 NK cell-specific SPPL3 deletion resulted in a defect in NK cell maturation similar 
to that seen in Vav1-SPPL3 KO mice (Fig. 2.4, E and F). NKp46-SPPL3 KO mice had 
fivefold fewer CD27+CD11b+ NK cells and ninefold fewer CD27-CD11b+ NK cells in the 
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spleen. In the bone marrow there was a 2.7-fold loss of CD27+CD11b+ cells and fourfold 
loss of CD27-CD11b+ cells. There was a small, 1.3-fold, but significant build-up of 
CD27+CD11b- cells in the bone marrow, with no change in the spleen. These results 
establish that SPPL3 is required in a cell-intrinsic manner for NK cell maturation. 
 To probe for molecular defects that might parallel the specific loss of 
CD27+CD11b+ and CD27-CD11b+ NK cells in NKp46-SPPL3 KO mice, we assayed the 
different maturation stages for cell surface expression of activating and inhibitory Ly49 
receptors, chemokine and cytokine receptors, adhesion molecules, as well as markers of 
NK cell differentiation that we had previously analyzed in the Vav1-SPPL3 KO model 
(Fig. 2.5 and Fig 2.6). Most of the molecules assayed displayed only subtle (less than 
twofold) changes in surface expression on NK cells from NKp46-SPPL3 KO mice 
without a selective change in CD11b+ stages that appeared to be most affected by SPPL3 
deletion. The largest effects observed were on integrin alpha V (CD51) and CD69. CD51 
was upregulated up to 4.4-fold in the spleen CD27-CD11b+ stage, and up to 2.4-fold in 
the same stage in the bone marrow (Fig. 2.5 E, F). CD69 was upregulated 3.7-fold in 
CD27-CD11b+ cells in the spleen, and 1.5-fold in the bone marrow. CD127 (the IL-7 
receptor) was also upregulated by 1.5- to 2.5-fold on all maturation subsets in the spleen 
in NKp46-SPPL3 KO mice (Fig. 2.5 B, D, F). All subsets in both the spleen and bone 
marrow displayed two- to threefold reductions in the activating receptor Ly49H, but not 
in the activating receptor NKG2D or in the inhibitory receptor Ly49G2. Activating 
receptors NK1.1 and NKp46 were also reduced up to twofold in all three maturation 
stages in NKp46-SPPL3 KO mice. Notably, the transcription factor eomesodermin, 
which is required for NK cell progression to the CD11b-expressing stage as well as 
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maintenance of the mature phenotype (4), was unaffected at any stage of maturation. The 
subtle changes in surface molecule expression that were measured in NKp46-SPPL3 KO 
mice did not obviously explain the cellular defects observed in NK cell maturation. 
 
 
Alterations in maturation can influence cytotoxicity 
 The terminal maturation program coincides with the acquisition of the full 
complement of activating and inhibitory receptors on NK cells (9–11). CD11blo NK cells 
from RAG1-deficient mice show reduced cytotoxic capacity against YAC-1 targets 
compared to CD11bhigh cells (10). Furthermore, CD27+CD11b+ NK cells from RAG1-
deficient mice display increased YAC-1 cytotoxicity compared to the most mature, 
CD27-CD11b+, NK cells (11). To test whether the reduction in cytotoxicity of SPPL3-
deficient NK cells could be at least partially attributed to their bulk population shift to a 
more immature status, we sorted wild type C57Bl/6J splenic NK cells into the three 
maturation stages (Fig. 2.7 A) and tested each in the YAC-1 lysis assay. CD27+CD11b- 
NK cells exhibited 55% of the cytotoxicity of the CD27+CD11b+ NK cells, which showed 
the maximum cytotoxic activity, and CD27-CD11b+ showed 65% of this activity (Fig. 
2.7, B and C). This determination allowed us to conclude that the change in distribution 
among these maturation stages in NKp46-SPPL3 KO mice can account for the functional 
per-cell cytoxicity defect observed in vitro.  
 
SPPL3 supports the proliferation and survival of NK cells but is not required for IL-15 
signaling 
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 The effect of SPPL3 deletion on NK cell maturation could be explained by 
changes in NK cell proliferation or death. To assay proliferation, splenic and bone 
marrow NK cells were stained for the proliferation marker Ki67. NKp46-SPPL3 KO cells 
showed a twofold reduction in percent Ki67+CD11b- NK cells in the bone marrow, from 
20% in control mice to 10% in NKp46-SPPL3 KO mice, with no change in the percent of 
Ki67+CD11b+ cells (Fig. 2.8 A). Splenic CD11b- NK cells showed no change in Ki67 
staining, and even a small increase in the CD11b+ fraction (6.8% in controls and 10.8% in 
NKp46-SPPL3 KO). The reduced CD11b- precursor proliferation in the bone marrow 
likely affects output to the periphery, potentially contributing to lower peripheral NK cell 
numbers. 
To assess cell death, we stained splenocytes and bone marrow lymphocytes with 
Annexin V. NKp46-SPPL3 KO CD11b- NK cells in the bone marrow actually showed a 
moderate reduction in cell death compared to control cells (14% in controls compared to 
10% in NKp46-SPPL3 KO), while no change in Annexin V staining was observed in 
splenic CD11b- NK cells. However, NKp46-SPPL3 KO CD11b+ NK cells showed a 
twofold increase in Annexin V staining in the bone marrow, from 15% to 34%, and a 
threefold increase in the spleen, from 11% to 38% (Fig. 2.8 B). These results suggest that 
SPPL3 is required both for proliferation of CD11b- NK cells and for the survival of 
CD11b+ NK cells that do make the transition from CD11b- precursors, which may 
account for the maturation defect seen in SPPL3-deficient animals.  
IL-15 signaling to immature NK cells regulates homeostatic proliferation in vivo, 
in part via the activation of the mTOR pathway, which regulates many metabolic 
processes (65). mTOR deficiency in NK cells results in a loss of mature, CD11b+ NK 
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cells similar to what we observed in NKp46-SPPL3 KO mice, and mTOR-deficient NK 
cells also show reduced proliferation in the bone marrow and reduced peripheral 
activation (23). We assayed the levels of three downstream markers of mTOR activity in 
freshly isolated NK cells: CD98, KLRG1, and cell size (Fig. 2.8 C-H). CD98 expression 
was only moderately reduced in the immature CD27+CD11b- bone marrow NK cells, to 
70% of control levels, and in the spleen to 79% of control levels (Fig. 2.8 D). KLRG1 
was reduced at all maturation stages, by as much as threefold in CD27-CD11b+ cells 
(Fig. 2.8 E-F), consistent with a defect in NK cell maturation that might or might not be 
mTOR-dependent. However, cell size was not reduced at all in any subtype in either bone 
marrow or spleen (Fig. 2.8 G-H), suggesting that mTOR activity in freshly isolated 
SPPL3-deficient NK cells is likely intact.   
We next tested the response of NKp46-SPPL3 KO NK cells to IL-15 by assaying 
the induction of phospho-S6 kinase and phosho-STAT5, both markers of mTOR 
activation, after 40 minutes of IL-15 stimulation. SPPL3-deficient NK cells from the 
bone marrow and spleen showed robust responses to IL-15 in these assays (Fig. 2.9 A-D). 
Moreover, proliferation in response to any dose of IL-15 was normal in SPPL3-deficient 
NK cells (Fig. 2.9 E-F). The results suggest that the absence of SPPL3 in NK cells does 
not impact IL-15 signaling to mTOR in immature NK cells and likely affects NK cell 
maturation through a different pathway. 
 
SPPL3 protease activity is required for normal peripheral NK cell frequency 
 Both proteolytic and non-proteolytic functions of SPPL3 have recently been 
reported. To address whether SPPL3 protease activity is required for its role in NK cell 
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biology, we used CRISPR/Cas9 genome editing in single cell zygotes to generate mice 
with a knock-in mutation of SPPL3 D271A (64). This residue is part of the YD and 
GXGD active site motif that is highly conserved among intramembrane aspartyl 
proteases and whose mutation to alanine has been shown to abrogate protease activity 
(54). SPPL3D271A/D271A mice displayed perinatal lethality similar to that observed with 
SPPL3-/- mice (Fig. 2.10 A). We next generated SPPL3fl/D271A/NKp46-iCre mice to 
engineer NK cell-specific expression of SPPL3 D271A in the absence of wild type 
SPPL3 (Fig. 2.10 B). These mice were obtained in Mendelian ratios and survived without 
overt phenotype. Genomic PCR and Western blot analysis of splenic NK cells sorted 
from SPPL3fl/D271A/ NKp46-iCre mice confirmed recombination of the floxed wild type 
SPPL3 allele and expression of SPPL3 D271A (Fig. 2.10, C and D). This demonstrated 
that the SPPL3 D271A mutant protein was expressed and that there was no selection for 
non-recombined NK cells. SPPL3fl/D271A/ NKp46-iCre mice exhibited no change in bone 
marrow NK cell number compared to control mice (SPPL3fl/+/NKp46-iCre), and a 2.9-
fold reduction in NK cell number in the spleen (Fig. 2.10 E). The results establish that 
SPPL3 protease activity is required in a cell-autonomous manner for normal numbers of 
peripheral NK cells. 
 
SPPL3 protease activity is required for normal NK cell maturation. 
 We next examined NK cell maturation in SPPL3fl/D271A/NKp46-iCre and control 
mice. SPPL3fl/D271A/NKp46-iCre mice exhibited a threefold reduction in CD27-CD11b+ 
NK cells in the bone marrow, and a sixfold reduction in the spleen (Fig. 2.11, A and B). 
There was a 1.8-fold loss of CD27+CD11b+ cells in the bone marrow, and a threefold loss 
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in the spleen. The bone marrow showed a moderate, 1.4-fold, increase in CD27+CD11b- 
NK cells, with no significant change in the spleen. This phenotype resembled that 
observed with SPPL3fl/fl/NKp46-iCre mice, indicating that SPPL3 protease activity is 
required for normal NK cell maturation.  
 
SPPL3 regulates MGAT5 expression in NK cells 
  SPPL3 has recently been reported to affect glycosylation in the Golgi through 
inhibitory cleavage and shedding of glycosyl transferases, such as MGAT5 (55, 56). In 
SPPL3-deficient MEFs, MGAT5 is retained within the cell and there is an increase in 
higher-order glycosylation (55). Consistent with previous reports, we found that SPPL3-
deficient NK cells isolated from NKp46-SPPL3 KO mice displayed an increase in 
MGAT5 intracellular expression (Fig. 2.12 A). We observed an apparent increase in the 
molecular weight of MGAT5 in SPPL3-deficient and protease-dead SPPL3-expressing 
NK cells. This is consistent with a previous report which found that in the absence of 
SPPL3, MGAT5 is retained in the cells as a mature, glycosylated species with slower 
migration on a gel (55). NK cells from SPPL3fl/D271A/NKp46-iCre mice also showed an 
increase in MGAT5 expression (Fig. 2.12 B), confirming a role for the protease activity 
of SPPL3 in MGAT5 regulation.  
 These results predicted that enhanced levels of intracellular MGAT5 activity 
would lead to higher levels of complex glycosylation on proteins expressed on the 
surface of NK cells. We tested this prediction by staining NKp46-SPPL3 KO and control 
NK cells with PHA-L, which detects GlcNac-β1,6-mannose glycosylation (66), and 
Concanavalin A, which detects mannose-containing lectins (67). Unexpectedly, PHA-L 
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surface staining on SPPL3-deficient NK cells from the spleen and bone marrow actually 
showed lower surface complex glycosylation levels (Fig. 2.12, C and D). In the bone 
marrow, PHA-L staining was reduced fourfold on CD11b- NK cells and fivefold on 
CD11b+ NK cells. In the spleen, PHA-L staining was reduced twofold on CD11b- NK 
cells and threefold on CD11b+ cells. Concanavalin A surface staining levels on these cells 
was minimally affected or unaffected (Fig. 2.12, E and F). The data argue against a 
simple model in which the phenotype of SPPL3-deficient NK cells is solely explained by 
enhanced complex glycosylation concomitant with the hyperactivity of MGAT5 and 
other glycosylation enzymes. Furthermore the reduction in complex glycosylation at the 
cell surface was consistent across NK cell maturation stages, while the biological effect 
of SPPL3 deletion was specifically observed in CD11b+ NK cells. Other targets of 
SPPL3 proteolytic activity are likely responsible for the changes in NK cell biology that 





 This work establishes the intramembrane aspartyl protease SPPL3 as a key 
regulator of NK cell maturation. Deletion of SPPL3 in the NK cell lineage leads to a 
specific loss in the steady state numbers of CD27+CD11b+ and CD27-CD11b+ NK cells. 
Our analysis suggests that this phenotype results from reduced proliferation of 
CD27+CD11b- precursors in the bone marrow and reduced survival of CD27+CD11b+ and 
CD27-CD11b+ NK cells in both the bone marrow and the periphery. Thus, SPPL3 plays 
specific, cell-autonomous roles that impact each of these stages of NK cell maturation. 
 SPPL3-deficient NK cells display clear defects in the ability to clear MHC Class 
I-deficient tumors in vivo and YAC-1 target cells in vitro. Our data demonstrate that at 
the different stages of NK cell maturation defined by CD27 and CD11b, NK cells possess 
differential cytotoxic potency on a per-cell basis. Previous studies have arrived at 
consistent conclusions. From RAG1-deficient animals, CD11blo NK cells show lower 
YAC-1 lysis than CD11bhi NK cells (10). Also from RAG1-deficient animals, 
CD27+CD11b+ show higher YAC-1 lysis than CD27-CD11b+ NK cells (11). Our data 
using NK cells from wild type mice confirm that CD27+CD11b+ NK cells are the most 
cytotoxic cells in this assay. Additionally, we have shown that CD27+CD11b- and CD27-
CD11b+ NK cells have equal cytolytic capabilities, both lower than the double positive 
NK cells. From this analysis, we estimate that the shift in maturation in SPPL3-deficient 
mice can account for the reduced cytotoxic potential observed in vitro. 
 While NKp46-iCre-mediated deletion of SPPL3 allowed us to conclude that 
SPPL3 exerts a cell-autonomous role in NK cell maturation, SPPL3 deletion in the 
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hematopoietic system with Vav1-iCre did result in a more pronounced buildup of 
CD27+CD11b- precursors in both the bone marrow and spleen, suggesting the possibility 
of a cell-nonautonomous role for SPPL3 in other hematopoietic cells that influence the 
transition from CD11b- NK cells to CD11b+ cells. Alternatively, SPPL3 may also be 
required cell-autonomously at an early stage in NK cell development, at a step prior to 
NKp46 expression, that later influences the CD11b- to CD11b+ transition. 
 Both protease-independent and protease-dependent functions for SPPL3 have 
recently been described (51, 55, 56). The phenotypes observed after expression of the 
protease-dead SPPL3 D271A allele in NK cells reveal that NK cell maturation relies on 
the proteolytic activity of SPPL3, and suggest that the protease-independent function of 
SPPL3 in facilitating store-operated calcium entry is not required in this context. 
Recently, SPPL3 has been shown to cleave and inhibit several enzymes that mediate 
complex glycosylation in the Golgi, including MGAT5. We were able to show that in NK 
cells, MGAT5 levels are indeed controlled by SPPL3 proteolytic activity. However, the 
increase in MGAT5 does not lead to the predicted increase in complex glycosylation on 
the surface of NK cells. Rather, a reduced overall level of complex glycosylation is 
observed, as revealed by PHA-L staining. This pattern is observed on both CD11b- and 
CD11b+ cells, while the biological effect of SPPL3 deletion is most pronounced on 
CD11b+ cells, suggesting that the changes in glycosylation do not simply account for the 
observed phenotypes in maturation and effector function. It is extremely likely that the 
lack of cleavage of other SPPL3 substrates is responsible for the phenotypes observed in 
mice lacking SPPL3 in NK cells. One possibility is that a particular substrate must be 
cleaved by SPPL3 at the CD27+CD11b- stage to maximize the proliferation of these cells 
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while another substrate must be cleaved to promote the survival of the CD11b+ stages. 
Alternatively, SPPL3 may be required to clear one or more substrates by cleavage, the 
buildup of which might be toxic to NK cells at specific CD11b- and CD11b+ stages of 
maturation. 
The molecular underpinnings of the terminal maturation program of NK cells are 
only beginning to emerge. In fact, to our knowledge, the only cell-autonomous pathway 
associated with a reduction of CD11b+ NK cells so far has been the IL-15-mTOR 
pathway. While SPPL3-deficient NK cells have a similar phenotype to mTOR-deficient 
NK cells in terminal maturation as well as proliferation in CD11b- bone marrow cells, our 
results suggest that SPPL3 functions in a distinct pathway. Activation of mTOR in 
response to IL-15 is intact in SPPL3-deficient immature NK cells. Additionally, mTOR-
deficient NK cells do not show the same changes in cell surface receptor expression that 
SPPL3-deficient NK cells do. Defining valid substrates for SPPL3 in this process holds 
high promise for adding to our understanding of the molecular determinants of NK cell 
maturation and optimal effector function.  
 The nonconditional deletion of SPPL3 results in postnatal lethality of 
undetermined cause. Death is likely not caused by autoimmunity or inflammation 
because conditional deletion of SPPL3 in the hematopoetic- or NK-cell lineages results in 
healthy pups. The same phenotype observed in our SPPL3 D271A knock-in mice 
indicates that this role for SPPL3 is also protease-dependent and very likely not related to 
the regulation of store-operated calcium entry. SPPL3D271A/+ mice are viable and overtly 
healthy, indicating that the SPPL3 D271A protein is not dominant negative. With the use 
of appropriate Cre transgenics, the conditional and knock-in mice we have generated 
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should make possible the identification of the cell type in which SPPL3 is required for 
postnatal viability. 
 In conclusion, our genetic analysis firmly places SPPL3 in the NK cell maturation 
pathway and establishes a novel entry point to investigate the molecular determinants that 
control NK cell biology. The role of SPPL3 in NK cells highlights the expanding roles of 










Figure 2.1. SPPL3 is required in the immune system for normal NK cells. (A) Expression 
of SPPL3 in C57Bl/6J splenocytes sorted on the indicated markers. Representative panel 
from three independent experiments with one mouse per experiment. (B) Kaplan-Meier 
survival curve of nonconditional SPPL3 knock-out mice (n=68 pups, p value was 
calculated by Mantel-Cox test). (C) Absolute number of lymphocytes in the spleen. 
Pooled data from three experiments with n=3-4 mice per genotype. (D) SPPL3 
expression in splenocytes isolated using the indicated Miltenyi negative isolation kits. 
Representative images from two independent experiments with n=1-2 mice per genotype. 
(E) Absolute number of NK cells (Lin-CD122+DX5+) in the indicated organs. Pooled data 
from four independent experiments with n=3-4 mice per genotype. (F) Western blot of 
splenic NK cells after negative isolation. Representative blot from four independent 
experiments with n=2-3 mice per genotype. (G) Percent RMA/s cells (of total RMA + 
RMA/s cells collected) remaining 48 hours after intraperitoneal injection. Pooled data 
from three independent experiments with n=2-8 mice per genotype. (H) Percent specific 
YAC-1 lysis after four-hour co-culture with isolated splenic NK cells (equivalent DX5+ 
cell number) at the indicated effector: target (E:T) ratios. Pooled data from three 
independent experiments with n=3 mice per genotype. For experiments in panels C, E, 
and G, each data point represents one mouse. **p<0.01, ***p<0.001, ****p<0.0001 
(two-tailed unpaired Student’s t-test with Welch’s correction). For experiments in panel 
H, each data point represents the mean of three pooled experiments. The data was 
analyzed by unpaired Student’s t test, and statistical significance determined using the 
Holm-Sidak method, with alpha=5.000%. Each ratio was analyzed individually, without  
RA 
Figure 2.1, continued 
assuming a consistent SD. 
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Figure 2.2. Gating strategy for NK cells. Representative flow panels diagramming the 
gating path for NK cells. Lymphocytes were gated first on size and granularity, then for 
lineage-negative cells, and finally for CD122+DX5+ cells. The right panels show the 
applicable Fluorescence Minus One (FMO) controls for drawing the gates. Top, spleen. 
Bottom, bone marrow. 
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Figure 2.3. SPPL3 is required for normal receptor expression and development of NK 
cells. (A) Representative flow panels of the NK cell gate (Lin-CD122+DX5+) showing the 
profile of the indicated receptors in the spleen. NK1.1 and DX5 negative controls are 
unstained cells, others are isotype controls. (B) The percentage of the NK cell gate that is 
positive for the indicated receptors as depicted in (A). (C) The median fluorescence 
intensity of the positive gates in (A) of indicated receptors on NK cells, calculated as a 
percent of the maximum for each receptor. (D) Representative flow panels of the NK cell 
gate in the indicated organs. (E) The absolute number of each maturation stage in NK 
cells. Pooled data from three independent experiments with n=3 mice per genotype. Each 
data point represents one mouse. **p<0.01, ***p<0.001, ****p<0.0001 (unpaired 
Student’s t-test, statistical significance determined using the Holm-Sidak method, with 





Figure 2.4. SPPL3 is required in a cell intrinsic manner for NK cell number and function. 
(A) Absolute number of NK cells in the spleen and bone marrow from NKp46-iCre mice. 
Pooled data from three experiments with n=3 mice per genotype. (B) Western blot 
showing SPPL3 expression in splenic NK cells sorted for Gr-1-DX5+ after NK cell 
isolation. Representative panel from two experiments with n=4-8 mice per genotype. (C) 
Percent RMA/s cells (of the total RMA + RMA/s cells collected) remaining 48 hours 
after injection. Pooled data from three independent experiments with n=2-10 mice per 
genotype. (D) Percent specific YAC-1 lysis after four-hour co-culture with isolated 
splenic NK cells (equivalent DX5+ cell number) at 2:1 E:T ratio. Pooled data from three 
independent experiments with n=3 mice per genotype. (E) Representative flow panels of 
the NK cell gate in the indicated organs. (F) The absolute number of cells in each 
maturation stage in NK cells. Pooled data from three independent experiments with n=3 
mice per genotype. Each data point represents one mouse, except YAC-1 lysis, where 
each data point represents the mean. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001 
(two-tailed unpaired Student’s t-test with Welch’s correction). For experiments in panel 
F, statistical significance was determined with an unpaired Student’s t-test using the 
Holm-Sidak method, with alpha=5.000%. Each row was analyzed individually, without 





Figure 2.5. Survey of expression of regulators in SPPL3-deficient NK cells. The relative 
mean fluorescence intensity of the indicated proteins are shown on NKp46-SPPL3 KO 
NK cells relative to NKp46-SPPL3 WT controls on CD27+CD11b- BM (A) and splenic 
NK cells (B), CD27+CD11b+ BM (C) and splenic NK cells (D), and CD27-CD11b+ BM 
(E) and splenic NK cells (F). Each data point represents the pooled mean of three 
independent experiments each with n=3-4 mice per genotype. *p<0.05 (unpaired 
Student’s t-test, statistical significance determined using the Holm-Sidak method, with 
alpha=5.000%. Each gene was analyzed individually, without assuming a consistent SD).  
  
 45 




Figure 2.6. Survey of expression of regulators in NKp46-SPPL3 KO NK cells. 
Representative flow panels of the indicated NK cell gate (Lin-CD122+DX5+) showing 
the profile of proteins in the spleen and bone marrow. The negative control is depicted in 
grey, NKp46-SPPL3 WT in blue, and NKp46-SPPL3 KO in red. CD51, DX5, and NK1.1 
negative controls are unstained cells, others are isotype controls. For NKp46, NKG2D, 
Eomes, and CXCR4, control mice are SPPL3 fl/+; NKp46-iCre. For all others, control 
mice are SPPL3 fl/fl. CD27+ is CD27+CD11b-, DP is CD27+CD11b+, CD11b+ is 
CD27-CD11b+. 
  




Figure 2.7. Maturation stage correlates with cytolytic function. (A) Representative flow 
panel showing the CD27 and CD11b gates used for sorting (Previously gated for single 
cells that were Gr-1-DX5+). (B) Representative flow panel of the CFSE+ gate after co-
culture. (C) Percent specific YAC-1 lysis after 3.5-hour co-culture with splenic NK cells 
sorted on the indicated receptors at a 2:1 E:T ratio. Each data point represents three 
pooled mice. Pooled data from three independent experiments with n=9 mice. p-value 
calculated using one-way ANOVA (with Tukey’s multiple comparisons test for 






Figure 2.8. SPPL3 regulates NK cell proliferation and survival in vivo. (A) Percent Ki67+ 
NK cells (Lin-CD122+DX5+) in the spleen and bone marrow. Pooled data from three 
experiments with n=3 mice per genotype. (B) Annexin V staining of splenic and bone 
marrow NK cells. Pooled data from three independent experiments with n=3-4 mice per 
genotype. (C, E, G) Representative flow panels showing the expression of CD98 (C), 
KLRG1 (E), and forward scatter (FSC, G) on the indicated NK cell gates in each organ. 
(D, F, H) Mean fluorescensce intensity of CD98 (relative, D), KLRG1 (relative, F), and 
FSC (absolute, H) on NKp46-SPPL3 KO NK cells in spleen and bone marrow, as 
compared to NKp46-SPPL3 wt controls. Pooled data from three independent experiments 
with n=3-4 mice per genotype. Each data point represents one mouse. *p<0.05, 
****p<0.0001 (unpaired Student’s t-test, statistical significance determined using the 
Holm-Sidak method, with alpha=5.000%. Each subset was analyzed individually, without 





Figure 2.9. SPPL3 does not affect IL-15 signaling. (A, C) Representative flow panels 
showing the expression of phospho-S6 and phospho-STAT5 in response to graded doses 
of IL-15 in NK cells in the bone marrow (A) and spleen (C). (B, D) Mean fluorescence 
intensity of phospho-S6 and phospho-STAT5 in the indicated NK cell subsets in response 
to graded doses of IL-15 in the bone marrow (B) and spleen (D). (E) Representative flow 
panels showing CFSE dilution in NK cells (DX5+AnnexinV- gate) after three day culture 
in graded doses of IL-15 (F) Percent of NK cells that had two or more divisions by CFSE 
dilution after three day culture in IL-15. Pooled data from three independent experiments 
with n=3-4 mice per genotype. Each data point represents the pooled mean. Results were 
analyzed for significance with an unpaired Student’s t-test, statistical significance 
determined using the Holm-Sidak method, with alpha=5.000%; *p<0.05. Each IL-15 dose 





Figure 2.10. SPPL3 protease activity is required in a cell-autonomous manner for normal 
NK cells. (A) Kaplan-Meier survival curve of SPPL3 D271A-expressing mice (n=115 
pups, p value was calculated by Mantel-Cox test). (B) Schematic of breeding strategy to 
create conditional expression of SPPL3 D271A exclusively within NK cells. (C) PCR on 
bulk cells (tail biopsy) or sorted splenic NK cells (Gr-1-DX5+) after isolation. Panels from 
a single experiment with n=4-8 mice per genotype. (D) Western blot of sorted splenic NK 
cells (Gr-1-DX5+) after isolation from mice of the indicated genotypes. Representative 
panels from two experiments with n=4-8 mice per genotype. (E) Absolute number of NK 
cells (Lin-CD122+DX5+) in the bone marrow and spleen. Pooled data from four 
experiments with n=3-4 mice per genotype. Each data point represents one mouse. 





Figure 2.11. SPPL3 protease activity is required in a cell-autonomous manner for normal 
NK cell maturation. (A) Representative flow panels of the NK cell gate (Lin-
CD122+DX5+) in the indicated organs. (B) The absolute number of cells in each 
maturation stage in NK cells. Pooled data from four independent experiments with n=3-4 
mice per genotype. Each data point represents one mouse. *p<0.05, ***p<0.001, 
****p<0.0001. Results were analyzed for significance with an unpaired Student’s t-test, 
statistical significance determined using the Holm-Sidak method, with alpha=5.000%. Each 





Figure 2.12. SPPL3 regulates glycosylation of NK cells. (A, B) Western blot of sorted 
splenic NK cells (Gr-1-DX5+) after isolation of the indicated genotypes. Representative 
panels from two independent experiments with n=4-8 mice per genotype. (C, E) Surface 
staining of PHA-L (C) and ConA (E) on NK cell gate (Lin-CD122+DX5+). Representative 
flow panels from spleen. (D, F) Median fluorescence intensity of PHA-L (D) and ConA 
(F) on NK cells from the indicated organs. Pooled data from three experiments with n=2-
3 mice per genotype. Each data point represents one mouse. *p<0.05, **p<0.01, 
***p<0.001, ****p<0.0001 Results were analyzed for significance with an unpaired 
Student’s t-test, statistical significance determined using the Holm-Sidak method, with 
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CHAPTER III: DISCUSSION 
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Intramembrane proteases play a key role in many signaling pathways. Often, 
proteolysis is regulated by sequestration of the protease and substrate in different cell 
membranes until an initiating event has occurred. Nearly all members of the aspartyl 
protease group play a role in the function of the innate and adaptive immune system. To 
eastablish a role for SPPL3 in vivo, we generated several strains of mice to conditionally 
delete SPPL3 in specific tissues or express a protease-dead mutant. This work 
eastablishes SPPL3 as a key checkpoint in NK cell maturation and creates several mouse 
models for further study of SPPL3 function in vivo. 
  NK cells are important cytotoxic lymphocytes in the immune system. By 
understanding the mechanisms that govern their maturation, we will gain valuable 
information about the regulation of immune cell function. The role of SPPL3 in the first 
transition of terminal maturation is a key checkpoint, as this is the final stage before NK 
cells achieve maximal cytotoxic capacity. Thus, SPPL3 may be a good target in the future 
for pharmacological modulation of NK cell function. A hyperactive immune response 
may be controlled by inhibiting SPPL3, or a suboptimal one may be enhanced by 
activating it.   
 SPPL3 appears to work through an unknown pathway in NK cell maturation. 
Only two other molecules are known to regulate this maturation step: eomesodermin and 
mTOR. Eomesodermin expression in SPPL3-deficient NK cells is normal. Assays of 
baseline mTOR signaling lead to inconsistent conclusions, but IL-15 signaling (thought 
to be the major pathway leading to mTOR activation in NK cells) is intact by several 
measures, both on short time scales as well as long term. It is our conclusion that SPPL3 
does not act through any of the known pathways to regulate NK cell maturation.  
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 This study established that SPPL3 acts as a protease in vivo and in the maturation 
of NK cells. The only well-studied target of SPPL3 cleavage is the glycosyl transferase 
MGAT5. While we believe MGAT5 shedding is prevented in SPPL3-deficient NK cells 
and may contribute to the phenotype, we do not believe that this is the directly relevant 
target because levels of this specific modification do not change over the course of 
maturation. If this enzyme is in the relevant pathway, its specific contribution to NK cell 
maturation must be teased apart to discover which glycosylation target regulates this 
process.  
 SPPL3 may play as yet unknown roles in the regulation of other cells of the 
immune system. Indeed, SPPL3 was identified as a positive regulator of NFAT activation 
downstream of TCR signaling using Jurkat T cells (51). Further work will be able to 
confirm if SPPL3 plays a role in this pathway in primary T cells. A complete, unbiased 
phenotypic characterization of the conditional SPPL3 deletion strain may uncover 
contributions to cells within the myeloid lineage as well.  
 Global deletion of SPPL3 or homozygous expression of the protease-dead mutant 
both resulted in perinatal lethality, within a day or so of birth. However, preliminary 
pathology performed on the pups was unable to identify a likely cause of death. A more 
detailed study would be required to find the cause. Since SPPL3 deletion within the 
immune system yielded healthy pups, SPPL3 likely plays a crucial role in another organ 
system. Future work with different Cre-recombinase drivers may be able to determine the 
relevant tissue to resolve this outstanding question.  
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 A bigger question also arises as to how SPPL3 may be regulated. Many other 
intramembrane proteases are regulated by access to substrates through entrapment of one 
or the other in different cell membranes. In response to an activating event, the substrate 
or protease will move through the secretory pathway into a compartment that shelters the 
protease or substrate. The current belief that SPPL3 is a constitutive sheddase is 
consistent with its static localization in the ER, an early compartment in the secretory 
pathway. Further studies will hopefully be able to address these outstanding questions in 
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